General and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Schedule of Inventory, Current [Table Text Block]

Inventories consist of the following at December 31 (in thousands):



	2017		2016
Raw material	$	82,397	$	28,435
Work in process	42,304		4,415
Finished goods	163,956		16,414
Total	$	288,657	$	49,264

Property, Plant and Equipment [Table Text Block]

Property, plant and equipment consist of the following at December 31 (in thousands):



	2017			2016
Machinery and equipment	$	220,999		$	96,536
Land, building and building improvements	206,846			63,524
Molds	56,253			39,014
Computer equipment and software	44,408			26,458
Furniture and fixtures	7,361			3,243
Instruments placed with customers*	15,812			—
Construction in progress	57,144			15,180
Total property, plant and equipment, cost	608,823			243,955
Accumulated depreciation	(210,139		)	(158,259		)
Net property, plant and equipment	$	398,684		$	85,696

______________________________

*Instruments placed with customers consist of drug-delivery and monitoring systems placed with customer under operating leases.

All property, plant and equipment are stated at cost. We use the straight-line method for depreciating property, plant and equipment over their estimated useful lives. Estimated useful lives are:



Buildings	15 - 30 years
Building improvements	15 years
Machinery and equipment	2 - 10 years
Furniture, fixtures and molds	2 - 5 years
Computer equipment and software	3 - 5 years
Instruments placed with customers*	3 - 7 years

Schedule of Intangible Assets and Goodwill [Table Text Block]

The following table presents the changes in the carrying amount of our goodwill for 2017 and 2016 (in thousands):



	Total
Balance as of December 31, 2015	$	6,463
Other⁽¹⁾	(886		)
Balance as of December 31, 2016	5,577
Goodwill acquired⁽²⁾	6,536
Other ⁽³⁾	244
Balance as of December 31, 2017	$	12,357

______________________________

⁽¹⁾In 2016, "other" relates to measurement period adjustments on the net assets of our 2015 acquisition of EXC Holding Corp. ("EXC").

⁽²⁾ In 2017, our Fannin (UK) Limited ("Fannin") acquisition resulted in $1.0 million of goodwill and our Medical Australia Limited ("MLA") acquisition resulted in $5.5 million of goodwill. The goodwill related to MLA is preliminary and subject to adjustment.

⁽³⁾In 2017, "other" relates to foreign currency translation.

Intangible Assets

Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):



	Weighted Average Amortization Life in Years	December 31, 2017
	Weighted Average Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	17,064	$	10,970	$	6,094
Customer contracts	9	5,319		4,892		427
Non-contractual customer relationships	9	55,080		6,562		48,518
Trademarks	4	425		425		—
Trade name	15	7,310		1,096		6,214
Developed technology	11	81,846		7,571		74,275
Total amortized intangible assets		$	167,044	$	31,516	$	135,528

IPR&D		$	8,225			$	8,225

Total intangible assets		$	175,269	$	31,516	$	143,753



	Weighted Average	December 31, 2016
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	14,423	$	9,326	$	5,097
MCDA contract *	10	8,571		8,571		—
Customer contracts	9	5,319		4,512		807
Non-contractual customer relationships	15	7,080		590		6,490
Trademarks	4	425		425		—
Trade name	15	7,310		609		6,701
Developed technology	10	3,797		509		3,288
Total		$	46,925	$	24,542	$	22,383

______________________________

*MCDA contract: Manufacturing, Commercialization and Development Agreement with Hospira, Inc., dated May 1, 2005 (the "MCDA”). The MCDA was terminated in connection with the acquisition of the HIS business on February 3, 2017.

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

As of December 31, 2017 estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands):



2018	$	15,996
2019	15,582
2020	15,444
2021	15,361
2022	15,242
Thereafter	57,903
Total	$	135,528

Available-for-sale Securities [Table Text Block]

As of December 31, 2017, our investment securities consist of the following (in thousands):



	December 31, 2017
	Amortized Cost		Unrealized Holding Gains (Losses)		Fair Value
Short-term corporate bonds	$	10,061	$	—	$	10,061
Long-term corporate bonds	14,579		—		14,579
Total investment securities	$	24,640	$	—	$	24,640

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands except per share data):



	Year ended December 31, (in thousands, except per share data)
	2017		2016		2015
Net income	$	68,644	$	63,084	$	44,985
Weighted average number of common shares outstanding (basic)	19,614		16,168		15,848
Dilutive securities ⁽¹⁾	1,244		1,086		648
Weighted average common and common equivalent shares outstanding (diluted)	20,858		17,254		16,496
EPS - basic	$	3.50	$	3.90	$	2.84
EPS - diluted	$	3.29	$	3.66	$	2.73

______________________________

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details